MDF and its international team of clinical care partners just met in Miami to draft consensus-based Care Considerations for doctors, pharmaceutical companies and federal regulators reviewing potential therapies. Read more in this article.
MDF's Interim Chief Science Officer, Dr. John Porter, brings a wealth of experience to MDF as a former academic researcher, program director at the National Institutes of health (NIH) and Chief Executive Officer of a patient advocacy organization. John offered his thoughts recently on the importance of patient advocacy in drug development.
Researchers from the University of Costa Rica and the University of Glasgow teamed up to investigate the DNA mutation causing myotonic dystrophy type 1 (DM1). They found that polymorphism in the MSH3 mismatch repair gene is associated with the levels of somatic instability of the expanded CTG repeat in the blood DNA of myotonic dystrophy type 1 patients.
Dr. Dixon at the University of Utah has been awarded a 2016-2017 postdoctoral fellowship for her research applying fMRI to evaluate connectivity networks in the brains of children with congenital-onset myotonic dystrophy (CDM). Read more here about the work of Dr. Dixon and her colleagues.
Dr. John Porter, former Program Director of Neuromuscular Disease at the National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health (NIH), has joined MDF as its Interim Chief Science Officer. Dr. Sharon Hesterlee, who formerly filled this position, will remain active as a member of MDF’s Scientific Advisory Committee.